These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28081968)

  • 1. The global distribution and diversity of protein vaccine candidate antigens in the highly virulent Streptococcus pnuemoniae serotype 1.
    Cornick JE; Tastan Bishop Ö; Yalcin F; Kiran AM; Kumwenda B; Chaguza C; Govindpershad S; Ousmane S; Senghore M; du Plessis M; Pluschke G; Ebruke C; McGee L; Sigaùque B; Collard JM; Bentley SD; Kadioglu A; Antonio M; von Gottberg A; French N; Klugman KP; Heyderman RS; Alderson M; Everett DB;
    Vaccine; 2017 Feb; 35(6):972-980. PubMed ID: 28081968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
    Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of Streptococcus pneumoniae in children living in southwest China and assessment of a potential protein vaccine, rPfbA.
    Yan Z; Cui Y; Zhou W; Li W; Tan X; Chen W; Zhang J; Jiang Y
    Vaccine; 2019 Jan; 37(5):721-731. PubMed ID: 30611601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against fatal pneumonia through mucosal and subcutaneous immunization with the pneumococcal SP0148 protein.
    Huang J; Luo S; Huang M; Zhang T; Min Z; Liu C; Zhang Q; Yang J; Min X
    Microb Pathog; 2019 Apr; 129():206-212. PubMed ID: 30772476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Immunization with the Commensal
    Shekhar S; Khan R; Schenck K; Petersen FC
    Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742
    [No Abstract]   [Full Text] [Related]  

  • 6. A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.
    Ochs MM; Williams K; Sheung A; Lheritier P; Visan L; Rouleau N; Proust E; de Montfort A; Tang M; Mari K; Hopfer R; Gallichan S; Brookes RH
    Hum Vaccin Immunother; 2016 Nov; 12(11):2946-2952. PubMed ID: 27392182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization.
    McCool TL; Cate TR; Tuomanen EI; Adrian P; Mitchell TJ; Weiser JN
    Infect Immun; 2003 Oct; 71(10):5724-32. PubMed ID: 14500493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Foster-Nyarko E; Owiafe PK; Ceesay F; Worwui A; Idoko OT; Owolabi O; Bojang A; Jarju S; Drammeh I; Kampmann B; Greenwood BM; Alderson M; Traskine M; Devos N; Schoonbroodt S; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2017 May; 35(19):2531-2542. PubMed ID: 28389097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of serotype-specific vaccination on phylodynamic parameters of Streptococcus pneumoniae and the pneumococcal pan-genome.
    Azarian T; Grant LR; Arnold BJ; Hammitt LL; Reid R; Santosham M; Weatherholtz R; Goklish N; Thompson CM; Bentley SD; O'Brien KL; Hanage WP; Lipsitch M
    PLoS Pathog; 2018 Apr; 14(4):e1006966. PubMed ID: 29617440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy.
    Dorosti H; Eslami M; Nezafat N; Fadaei F; Ghasemi Y
    Mol Cell Probes; 2019 Dec; 48():101446. PubMed ID: 31520715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism.
    Visan L; Rouleau N; Proust E; Peyrot L; Donadieu A; Ochs M
    Hum Vaccin Immunother; 2018 Feb; 14(2):489-494. PubMed ID: 29135332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotype-Independent Protection Against Invasive Pneumococcal Infections Conferred by Live Vaccine With
    Jang AY; Ahn KB; Zhi Y; Ji HJ; Zhang J; Han SH; Guo H; Lim S; Song JY; Lim JH; Seo HS
    Front Immunol; 2019; 10():1212. PubMed ID: 31191555
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine.
    Dorosti H; Eslami M; Negahdaripour M; Ghoshoon MB; Gholami A; Heidari R; Dehshahri A; Erfani N; Nezafat N; Ghasemi Y
    J Biomol Struct Dyn; 2019 Aug; 37(13):3524-3535. PubMed ID: 30634893
    [No Abstract]   [Full Text] [Related]  

  • 19. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
    Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.
    Verhoeven D; Perry S; Pichichero ME
    Clin Vaccine Immunol; 2014 Aug; 21(8):1037-45. PubMed ID: 24850621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.